公开(公告)号：US20240366539A1

公开(公告)日：2024-11-07

申请号：US18685000

申请日：2022-09-02

Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ DE TOURS

Inventor： Jérôme BECKER ,  Julie LE MERRER

IPC: A61K31/167 ,  A61K33/00 ,  A61P25/00

Abstract: Autism Spectrum Disorders (ASD) are neurodevelopmental disorders whose diagnosis relies on deficient social interaction and communication together with repetitive behavior. To date, no pharmacological treatment has been approved that ameliorates social behavior in patients with ASD. Based on the excitation/inhibition imbalance theory of autism, the Inventors hypothesized that bromide ions, long used as an antiepileptic medication, could relieve core symptoms of ASD. They evaluated the effects of chronic sodium bromide (NaBr) administration on autistic-like symptoms in three genetic mouse models of autism: Oprm1−/−, Fmr1−/− and Shank3Δex13-16−/− mice. They showed that chronic NaBr treatment relieved autistic-like behaviors in these three models. In Oprm1−/− mice, these beneficial effects were superior to those of chronic bumetanide administration. At transcriptional level, chronic NaBr in Oprm1 null mice was associated with increased expression of genes coding for chloride ions transporters, GABAA receptor subunits, oxytocin and mGlu4 receptor. Lastly, they uncovered synergistic alleviating effects of chronic NaBr and a positive allosteric modulator (PAM) of mGlu4 receptor on autistic-like behavior in Oprm1−/− mice. They evidenced in heterologous cells that bromide ions behave as PAMs of mGlu4, providing a molecular mechanism for such synergy. Their data reveal the therapeutic potential of bromide ions, alone or in combination 0 with a PAM of mGlu4 receptor, for the treatment of ASDs.

公开(公告)号：US12123058B2

公开(公告)日：2024-10-22

申请号：US16963948

申请日：2019-01-25

Applicant: SORBONNE UNIVERSITE ,  CTRE RECHERCHE PATHOLOGIES PROSTATIQUES ,  LIGUE NATIONALE CONTRE LE CANCER ,  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE TOURS ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS

Inventor： Olivier Cussenot ,  Aurélie Kamoun ,  Aurélien De Reynies ,  Géraldine Cancel-Tassin ,  Gaëlle Fromont-Hankard

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.

公开(公告)号：US10736947B2

公开(公告)日：2020-08-11

申请号：US16003936

申请日：2018-06-08

Applicant: UNIVERSITÉ DE TOURS ,  KYMERIS THERAPEUTICS INC. ,  Institut national de recherche pour l' agriculture, l' alimentation et l'environneement

Inventor： Isabelle Dimier-Poisson ,  Marie-Noëlle Mevelec ,  Céline Ducournau ,  Nathalie Moire ,  Richard McCrae

IPC: A61K39/00 ,  A61K35/68 ,  A61P35/00

Abstract: The present invention relates to a strain of Neospora caninum for use in treating cancer or infectious diseases.

公开(公告)号：US09731005B2

公开(公告)日：2017-08-15

申请号：US14428588

申请日：2013-09-13

Applicant: UNIVERSITÉ DE DROIT ET DE SANTÉ DE LILLE II ,  UNIVERSITÉ DE TOURS FRANCOIS RABELAIS ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE LILLE

Inventor： Didier Betbeder ,  Isabelle Dimier-Poisson ,  Céline Ducournau

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/04 ,  A61K39/39 ,  A61K9/00 ,  A61K9/51 ,  A61K39/002 ,  A61K47/48

CPC classification number: A61K39/39 ,  A61K9/0043 ,  A61K9/5123 ,  A61K9/5161 ,  A61K39/00 ,  A61K39/002 ,  A61K47/6939 ,  A61K2039/543 ,  A61K2039/55555 ,  A61K2039/57 ,  A61K2039/6018 ,  A61K2039/6087 ,  Y02A50/487 ,  Y02A50/489 ,  Y02A50/491

Abstract: A pharmaceutical composition for its use in the prophylactic treatment of a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid, without said cationic-polysaccharide core being surrounded by any phospholipidic layer, and at least an antigen obtained from said pathogen.

公开(公告)号：US20150238598A1

公开(公告)日：2015-08-27

申请号：US14428588

申请日：2013-09-13

Applicant: UNIVERSITÉ DE DROIT ET DE SANTÉ DE LILLE II ,  UNIVERSITÉ DE TOURS FRANCOIS RABELAIS ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE LILLE

Inventor： Didier Betbeder ,  Isabelle Dimier-Poisson ,  Céline Ducournau

IPC: A61K39/39 ,  A61K9/51 ,  A61K39/002 ,  A61K9/00

CPC classification number: A61K39/39 ,  A61K9/0043 ,  A61K9/5123 ,  A61K9/5161 ,  A61K39/00 ,  A61K39/002 ,  A61K47/6939 ,  A61K2039/543 ,  A61K2039/55555 ,  A61K2039/57 ,  A61K2039/6018 ,  A61K2039/6087 ,  Y02A50/487 ,  Y02A50/489 ,  Y02A50/491

Abstract: A pharmaceutical composition for its use in the prophylactic treatment in a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid without being surrounded by any phospholipidic layer and at least an antigen obtained from said pathogen.

Abstract translation: 一种药物组合物，其用于预防性治疗患者体内的细胞内病原体，所述组合物包含固体纳米颗粒，所述固体纳米颗粒包含多孔阳离子 - 多糖固体核心，其负载至少一种阴离子磷脂而不被任何磷脂层包围，并且至少 从所述病原体获得的抗原。

公开(公告)号：US20240058481A1

公开(公告)日：2024-02-22

申请号：US18253953

申请日：2021-11-23

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITÉ DE TOURS ,  UNIVERSITE D'ORLEANS

Inventor： Sylvain ROUTIER ,  Frédéric BURON ,  Franck SUZENET ,  Nuno RODRIGUES ,  Sylvie CHALON ,  Johnny VERCOUILLIE ,  Denis GUILLOTEAU ,  Patrick EMOND ,  Hamid MARZAG

IPC: A61K51/04 ,  C07D211/14 ,  C07F5/02

CPC classification number: A61K51/0455 ,  C07D211/14 ,  C07F5/025

Abstract: The present invention relates to the radiolabelled compound of enantiomer (R,R) of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol, and to this compound for use thereof in an in vivo diagnosis method, in particular of a cholinergic neurodegenerative disease selected for example from the group formed by Alzheimer's disease, dysmnesia, learning disability, schizophrenia, cognitive dysfunction, hyperactivity disorder, anxiety neurosis, depression, analgesia and Parkinson's disease.

公开(公告)号：US20230372416A1

公开(公告)日：2023-11-23

申请号：US18248120

申请日：2021-10-08

Applicant: UNIVERSITÉ DE TOURS ,  INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

Inventor： Nathalie HEUZE-VOURC'H ,  Thomas SECHER ,  Muriel THOMAS

IPC: A61K35/747 ,  A61P31/04 ,  A61K39/40 ,  A61P11/00 ,  A61K9/00

CPC classification number: A61K35/747 ,  A61P31/04 ,  A61K39/40 ,  A61P11/00 ,  A61K9/0073 ,  A61K2039/544

Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.

公开(公告)号：US20230287031A1

公开(公告)日：2023-09-14

申请号：US18005709

申请日：2021-07-16

Applicant: UNIVERSITÉ DE BRETAGNE OCCIDENTALE ,  UNIVERSITÉ DE TOURS ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE

Inventor： Paul Alain JAFFRES ,  Hélène COUTHON ,  Charlotte SEVRAIN ,  Alicia BAUDUIN ,  Christophe VANDIER ,  Aurélie CHANTÖME ,  Delphine FONTAINE

IPC: C07H15/04 ,  A61P9/00

CPC classification number: C07H15/04 ,  A61P9/00

Abstract: New glycolipids derivatives of Formula (I)




and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. Also, pharmaceutical compositions including compounds of Formula (I) for use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels.

公开(公告)号：US20230236122A1

公开(公告)日：2023-07-27

申请号：US17927480

申请日：2021-05-24

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS ,  UNIVERSITÉ DE TOURS

Inventor： Olivier HERAULT ,  Olivier SIRE

IPC: G01N21/3577

CPC classification number: G01N21/3577 ,  G01N2021/3595

Abstract: A method for determining the risk of developing a blood disorder, which includes the steps of: exposing a biological sample from an individual to radiation to obtain a spectrum characteristic of the sample, the spectrum being processed in order to obtain a spectral signature; comparing the spectral signature obtained with one or more reference spectral signatures; and concluding, if the spectral signature of the individual is significantly different from control spectral signatures, that the individual is likely to develop a blood disorder, and, if not, that the individual is not likely to develop a blood disorder.

公开(公告)号：US20220233607A1

公开(公告)日：2022-07-28

申请号：US17614771

申请日：2020-05-29

Applicant: UNIVERSITÉ DE TOURS ,  KYMERIS THERAPEUTICS INC. ,  INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT

Inventor： Isabelle DIMIER-POISSON ,  Marie-Noëlle MEVELEC ,  Anne DI TOMMASO ,  Nicolas AUBREY ,  Louis LANTIER ,  Gordon LEE

IPC: A61K35/68 ,  C07K14/54 ,  C07K14/715 ,  C07K14/77 ,  C07K16/28

Abstract: A strain of an Apicomplexa of the family Sarcocystidae, wherein the strain is replicative and expresses one or more heterologous protein(s) selected from the group including therapeutic proteins, antigens, recombinant surface receptor or combinations thereof, and wherein the strain is selected from the group including Toxoplasma gondii and Neospora caninium. Also, the use of the strain for preventing or treating cancers or infectious diseases in a subject in need thereof.